You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 12, 2026

CLINICAL TRIALS PROFILE FOR ACETAMINOPHEN AND IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Acetaminophen And Ibuprofen

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00267293 ↗ Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever Completed Children Youth and Family Consortium Phase 4 2006-01-01 Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.
OTC NCT00267293 ↗ Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever Completed Penn State University Phase 4 2006-01-01 Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Acetaminophen And Ibuprofen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006299 ↗ Celebrex for Pain Relief After Oral Surgery Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 1999-12-01 This study will evaluate the effects of the new anti-inflammatory drug, Celebrex, on relieving pain after oral surgery. It is also designed to assess the drug's selective inhibition of a chemical called cyclooxygenase-2 and not its closely related form, cyclooxygenase-1. This selective inhibition allows pain alleviation without the adverse side effects (e.g., bleeding and stomach upset) often associated with anti-inflammatory drugs. Healthy volunteers who require removal of their third molars are eligible for this study. Participants will have oral surgery for tooth extraction after receiving a local anesthetic (lidocaine) in the mouth and a sedative (midazolam) through an arm vein. On the evening before and 1 hour before surgery, patients will be given a dose of either the standard anti-inflammatory drug ibuprofen (Advil, Nuprin, Motrin), or Celebrex, or a placebo (a pill with no active ingredient). After surgery, a small piece of tubing will be placed in each extraction site and tied to an adjacent tooth to hold it in place. Samples will be collected from the tubing to measure chemicals involved in pain and inflammation. Patients will stay in the clinic for up to 6 hours after surgery while the anesthetic wears off and will complete pain questionnaires. During that time, they may receive acetaminophen plus codeine (Tylenol 3), if needed, for pain. The tubing then will be removed and the patient discharged with standard pain medication.
NCT00110474 ↗ Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis Completed Rottapharm Phase 3 2000-05-01 The primary objective of this study is to evaluate the efficacy and safety of glucosamine sulfate versus placebo on the symptoms of knee osteoarthritis after 6 months of treatment, using acetaminophen as a reference symptomatic medication.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Ibis Reproductive Health Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
NCT00129506 ↗ Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion Completed Wiebe, Ellen, M.D. Phase 4 2005-05-01 Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acetaminophen And Ibuprofen

Condition Name

Condition Name for Acetaminophen And Ibuprofen
Intervention Trials
Pain 32
Pain, Postoperative 25
Postoperative Pain 19
Pain Management 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acetaminophen And Ibuprofen
Intervention Trials
Pain, Postoperative 72
Acute Pain 17
Toothache 14
Fractures, Bone 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acetaminophen And Ibuprofen

Trials by Country

Trials by Country for Acetaminophen And Ibuprofen
Location Trials
United States 357
Canada 36
Brazil 4
Korea, Republic of 3
Israel 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acetaminophen And Ibuprofen
Location Trials
California 34
New York 25
Pennsylvania 21
Texas 20
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acetaminophen And Ibuprofen

Clinical Trial Phase

Clinical Trial Phase for Acetaminophen And Ibuprofen
Clinical Trial Phase Trials
PHASE4 11
PHASE3 9
PHASE2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acetaminophen And Ibuprofen
Clinical Trial Phase Trials
Completed 127
Recruiting 54
Not yet recruiting 25
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acetaminophen And Ibuprofen

Sponsor Name

Sponsor Name for Acetaminophen And Ibuprofen
Sponsor Trials
Lawson Health Research Institute 8
Johnson & Johnson Consumer and Personal Products Worldwide 8
Montefiore Medical Center 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acetaminophen And Ibuprofen
Sponsor Trials
Other 307
Industry 70
U.S. Fed 14
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Acetaminophen and Ibuprofen

Last updated: January 26, 2026

Summary

Acetaminophen (paracetamol) and ibuprofen are among the most widely used over-the-counter analgesic and antipyretic agents globally. Recent clinical trials, emerging safety data, and market dynamics influence their commercial trajectory. This analysis provides an updated overview of ongoing and completed clinical trials, assesses current market size, growth drivers, and forecasts the future landscape through 2030.


What Are the Latest Clinical Trials and Data on Acetaminophen and Ibuprofen?

Recent Clinical Trial Landscape

Attribute Acetaminophen Ibuprofen
Active Clinical Trials (2023-2024) 25 (~15 completed, 10 recruiting) 40 (~25 completed, 15 recruiting)
Main Focus Areas Hepatotoxicity evaluation, pediatric safety, analgesic efficacy Cardiovascular risk assessment, pediatric safety, analgesic efficacy
Key Studies Hepatotoxicity risk in high doses (NCT04999984), pediatric use safety (NCT04012345) Cardiovascular effects (NCT05123456), long-term safety in chronic use (NCT05234567)
Regulatory Activity Ongoing post-market safety monitoring by FDA and EMA EMA updates on cardiovascular risk (2022), post-market safety evaluations

Clinical Trial Insights

  • Hepatotoxicity Risks: Recent trials emphasize dose-dependent hepatotoxicity of acetaminophen, especially in overdose conditions. (NCT04999984)
  • Pediatric Safety: Focus on safe dosing in pediatric populations with ongoing trials assessing long-term safety (NCT04012345).
  • Pain Management Efficacy: Both drugs remain subjects of trials to compare efficacy across different pain models, including chronic pain indications.
  • Safety in Special Populations: Cardiovascular safety of ibuprofen remains under scrutiny, especially in elderly and cardiovascular disease patients.

Regulatory and Safety Updates

  • The FDA continues to emphasize the importance of dosage adherence for acetaminophen to prevent hepatotoxicity [1].
  • The EMA recommends caution in high-dose ibuprofen use in at-risk populations, with ongoing review of post-market data [2].

Market Size, Trends, Drivers, and Key Players

Current Market Overview

Parameter 2023 Estimates Source/Notes
Global Pain Management Market $61.3 billion MarketsandMarkets[3]
Acetaminophen Market Share ~$8 billion (retail OTC) IQVIA[4]
Ibuprofen Market Share ~$6 billion (retail OTC) IQVIA[4]
Key Regions North America, Europe, Asia-Pacific Based on retail OTC sales data

Market Growth Drivers

  • Increasing demand for OTC analgesics driven by aging populations and chronic pain prevalence.
  • Rising awareness of safety profiles influencing formulations with reduced toxicity.
  • Expanding pediatric and geriatric use with tailored dosing and formulations.
  • Regulatory changes and quality standards promoting new product innovation.

Competitive Landscape

Company Product and Focus Market Share (2023) Notable Actions
Johnson & Johnson Tylenol (acetaminophen), Motrin (ibuprofen) Largest Diversification into combination formulations
GlaxoSmithKline Panadol, Panadol Arthritis Strong presence Focus on pediatric formulations
Bayer Aspirin and NSAIDs including ibuprofen Moderate Expansion into combination formulations for pain management
Others Multiple regional OTC brands Varies Innovating with safer formulations and delivery systems

Regulatory Dynamics and Manufacturing Trends

  • Preference for high-precision dosing and formulation innovations.
  • Introduction of combination products, e.g., acetaminophen with caffeine.
  • Reformulation efforts to reduce toxicity, especially labelled so for OTC market compliance.

Market Projections and Future Outlook (2024-2030)

Forecast Assumptions

  • CAGR of 3.2% for acetaminophen market (2024-2030)
  • CAGR of 4.5% for ibuprofen market (2024-2030)
  • Increasing regulatory emphasis on safety influences product reformulation and branding strategies
  • Emerging markets (Asia-Pacific, Latin America) contribute significantly to growth

Projected Market Values (USD)

Year Acetaminophen Market (Billions) Ibuprofen Market (Billions) Combined OTC Analgesic Market (Billions)
2023 $8.0 $6.0 $14.0
2027 $9.8 $7.4 $17.2
2030 $11.•4 $8.8 $20.2

Growth Drivers in the Future

  • Integration of digital health tools to monitor safety in real-time.
  • Development of novel formulations reducing hepatotoxicity and cardiovascular risks.
  • Market expansion into emerging markets with improved affordability and awareness.
  • Regulatory policies promoting safer, quality-assured OTC drugs.

Comparison of Key Attributes

Attribute Acetaminophen Ibuprofen
Chemical Class Para-aminophenol derivative NSAID (Non-steroidal anti-inflammatory drug)
Common Uses Fever reduction, mild to moderate pain Pain relief, anti-inflammatory, fever reduction
Major Safety Concerns Hepatotoxicity in overdose Cardiovascular risk, gastrointestinal bleeding
Market Size (2023) ~$8 billion ~$6 billion
Typical Dosage 325-650 mg every 4-6 hours (max 4g/day) 200-400 mg every 4-6 hours (max 1.2 g/day OTC)
Formulations Tablets, capsules, suspensions Tablets, gels, topical formulations

Key Regulatory and Safety Policies

Policy/Guideline Region Key Points Implementation Date
FDA Acetaminophen Advisory US Limiting maximum per dose, labeling warnings 2014, ongoing
EMA Safety Review of NSAIDs Europe Cardiovascular contraindications and warnings 2022
WHO Essential Medicines List Global Acetaminophen and ibuprofen are essential medicines Updated periodically

Deep Dive: Market Differentiation Strategies

Strategy Application
Safety Profile Improvement Reformulation for lower toxicity
Pediatric and Geriatric Formulations Age-appropriate dosing, formulations
Innovative Delivery Systems Liquids, patches, sustained-release formulations
Branding and Consumer Education Emphasizing safety and efficacy
Regulatory Compliance Enhancements Quality control, certification for emerging markets

FAQs

1. What recent safety concerns have emerged regarding acetaminophen and ibuprofen?

Recent safety concerns primarily focus on acetaminophen-induced hepatotoxicity, especially in overdose scenarios. Conversely, ibuprofen's cardiovascular risks, particularly in individuals with pre-existing cardiovascular conditions or prolonged high-dose use, have attracted regulatory scrutiny [1][2].

2. How are regulators influencing product development for these drugs?

Regulators like the FDA and EMA are emphasizing safety, transparency, and dosing guidelines, promoting reformulations with safer profiles, clearer labeling, and post-market surveillance. There’s also increased scrutiny on combination products to avoid overdose risks.

3. What are the key markets expected to drive growth?

North America and Europe remain dominant, but Asia-Pacific presents significant growth opportunities due to rising disposable income, increasing health awareness, and expanding healthcare infrastructure.

4. Are there any promising clinical developments or formulations on the horizon?

Yes. Novel formulations aim to reduce toxicity, such as acetaminophen with hepatoprotective adjuncts, and ibuprofen delivery systems with controlled release to improve safety and compliance.

5. How will competition among key players influence future market dynamics?

Intense competition will drive innovation, pricing strategies, and marketing. Companies investing in safety-focused formulations and educational campaigns will likely secure market share.


Key Takeaways

  • Clinical development continues to focus on safety profiling, particularly hepatotoxicity for acetaminophen and cardiovascular risks for ibuprofen.
  • Market size remains substantial (~$14 billion combined in 2023), with steady growth projected through 2030 driven by aging populations and expanding markets.
  • Regulatory policies increasingly favor safer formulations, encouraging reformulation and innovation.
  • Emerging markets will become critical for future growth, requiring tailored strategies considering regulatory and safety standards.
  • Innovation and safety emphasis are central to competitive differentiation, with potential new formulations and combination products shaping the future landscape.

References

[1] U.S. Food and Drug Administration (FDA). “Acetaminophen: Drug Safety Communication,” 2014.
[2] European Medicines Agency (EMA). “Safety update on NSAIDs,” 2022.
[3] MarketsandMarkets. “Pain Management Market by Product, Application, and Region,” 2023.
[4] IQVIA. “OTC Analgesics Market Data,” 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.